Ahmedabad, Gujarat — Cadila Pharmaceuticals Limited, one of India’s most respected and innovation-driven pharmaceutical companies, has announced the launch of Biscado (Bisoprolol), marking its foray into the dynamic and fast-growing field of beta-blocker therapy, a vital component in the treatment of cardiovascular diseases.
A timely solution for India’s growing cardiac burden
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure, angina (chest pain), and chronic heart failure. By reducing heart rate and blood pressure, it eases the strain on the heart and has been shown to significantly improve survival and reduce hospitalisations in heart failure patients.
The relevance of Biscado in India is particularly significant. Indians are predisposed to higher sympathetic activity and elevated resting heart rates, which are well-recognised predictors of poor cardiovascular outcomes. Studies have shown that an increase of just 10 beats per minute in resting heart rate is associated with a 20% increase in the risk of cardiovascular death.
“India is at the epicentre of a cardiovascular epidemic, and elevated heart rate is a major modifiable risk factor. With the launch of Biscado, Cadila Pharmaceuticals brings a powerful, clinically proven solution to physicians and patients right when it is needed most,” said a senior spokesperson at Cadila Pharmaceuticals Limited.
The launch of Biscado reflects Cadila Pharmaceuticals’ commitment to meeting unmet medical needs and expanding its presence in the cardiovascular segment.
Clinically proven and globally recommended
Biscado is supported by extensive clinical research, including the landmark CIBIS-II (Cardiac Insufficiency Bisoprolol Study), which demonstrated a 34% reduction in all-cause mortality, a 44% reduction in sudden cardiac death, and a 36% reduction in hospitalisation due to worsening heart failure.
Other studies have reinforced Bisoprolol’s superiority with a 20% lower risk of mortality compared to Metoprolol Succinate and better mortality outcomes than Carvedilol in chronic heart failure patients. A TIBBS study showed that in stable angina, Biscado users had lower rates of death, myocardial infarction, and hospitalisation, versus patients treated with calcium channel blockers.
The medication has demonstrated high tolerability even in patients with heart failure, and it remains a cornerstone drug in clinical guidelines, including those by the European Society of Cardiology, European Society of Hypertension, and American Heart Association / American College of Cardiology.
Comprehensive cardiovascular care
Beyond its mono-therapy form, Biscado will be introduced in Fixed-Dose Combinations with other antihypertensive agents, covering the entire spectrum of cardiovascular management. This aligns with clinical practices that now advocate combination therapy for better patient adherence and enhanced control of multiple CV risk factors.
With its once-a-day dosing, favourable safety profile, and proven impact on survival, Biscado stands out as a preferred choice for physicians aiming to manage hypertension, angina, and heart failure holistically.
“Bless the Hearts” is more than a tagline
Biscado’s launch is accompanied by the campaign theme: “Bless the Hearts”. This reflects Cadila Pharmaceuticals’ deeper purpose of improving cardiac outcomes, enhancing quality of life, and bringing hope to lakhs of Indian patients at risk of heart disease. It also echoes the company’s larger mission of delivering value through innovation and compassionate healthcare.
